Digital ischemia in scleroderma spectrum of diseases

International Journal of Rheumatology

Volumn 2010, Issue , 2010, Pages

  Schiopu, Elena ^a   Impens, Ann J ^a   Phillips, Kristine ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CARBON MONOXIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA TOPOISOMERASE; ENDOTHELIAL CELL ANTIBODY; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; LOSARTAN; NIFEDIPINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; QUINAPRIL; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST;

BRACHIAL ANGIOGRAPHY; DIGIT ULCER; DIGITAL UCLER; DIGITAL ULCER; DISEASE ASSOCIATION; HEALTH EDUCATION; HUMAN; INCIDENCE; INJECTION SITE PAIN; LOW DRUG DOSE; LUNG DIFFUSION CAPACITY; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVASCULARIZATION; REVIEW; RISK FACTOR; SMOKING; SYMPATHECTOMY; SYSTEMIC SCLEROSIS; ULCER; ULCER HEALING; UNSPECIFIED SIDE EFFECT;

EID: 79955085750     PISSN: 16879260     EISSN: 16879279     Source Type: Journal    
DOI: 10.1155/2010/923743     Document Type: Review

References (55)

1. Wigley F. M., Flavahan N. A., Raynaud's phenomenon Rheumatic Disease Clinics of North America 1996 22 4 765 781 (Pubitemid 26396050)
2. Herrick A. L., Roberts C., Tracey A., Silman A., Anderson M., Goodfield M., McHugh N., Muir L., Denton C. P., Lack of agreement between rheumatologists in defining digital ulceration in systemic sclerosis Arthritis and Rheumatism 2009 60 3 878 882
3. Korn J. H., Mayes M., Matucci Cerinic M., Rainisio M., Pope J., Hachulla E., Rich E., Carpentier P., Molitor J., Seibold J. R., Hsu V., Guillevin L., Chatterjee S., Peter H. H., Coppock J., Herrick A., Merkel P. A., Simms R., Denton C. P., Furst D., Nguyen N., Gaitonde M., Black C., Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist Arthritis and Rheumatism 2004 50 12 3985 3993 (Pubitemid 39643947)
4. Amanzi L., Braschi F., Fiori G., Digital ulcers in scleroderma: staging, characteristics and sub-setting through observatoin of 1614 digital lesions Rheumatology 2010 49 7 1374 1382
5. Rodnan G. P., Myerowitz R. L., Justh G. O., Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud's phenomenon Medicine 1980 59 6 393 408 (Pubitemid 11241561)
6. Carvalho D., Savage C. O. S., Black C. M., Pearson J. D., IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro: induction of adhesion molecule expression and involvement of endothelium-derived cytokines The Journal of Clinical Investigation 1996 97 1 111 119
7. Sgonc R., Gruschwitz M. S., Boeck G., Sepp N., Gruber J., Wick G., Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95 Arthritis and Rheumatism 2000 43 11 2550 2562
8. Lau C. S., McLaren M., Saniabadi A., Belch J. J. F., Increased whole blood platelet aggregation in patients with Raynaud's phenomenon with or without systemic sclerosis Scandinavian Journal of Rheumatology 1993 22 3 97 101 (Pubitemid 23198110)
9. Wigley F. M., Korn J. H., Csuka M. E., Medsger T. A. Jr., Rothfield N. F., Ellman M., Martin R., Collier D. H., Weinstein A., Furst D. E., Jimenez S. A., Mayes M. D., Merkel P. A., Gruber B., Kaufman L., Varga J., Bell P., Kern J., Marrott P., White B., Simms R. W., Phillips A. C., Seibold J. R., Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis Arthritis and Rheumatism 1998 41 4 670 677
10. Pope J. E., Bellamy N., Sample size calculations in scleroderma: a rational approach to choosing outcome measurements in scleroderma trials Clinical and Investigative Medicine 1995 18 1 1 10
11. Tiev K. P., Diot E., Clerson P., Clinical features of scleroderma patients with or without prior or current ischemic digital ulcers: post-hoc analysis of a nationwide multicenter cohort (ItinerAIR-Sclerodermie) The Journal of Rheumatology 2009 36 7 1470 1476
12. Sunderkotter C., Herrgott I., Brckner C., Moinzadeh P., Pfeiffer C., Ger J., Hunzelmann N., Bhm M., Krieg T., Mller-Ladner U., Genth E., Schulze-Lohoff E., Meurer M., Melchers I., Riemekasten G., Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors British Journal of Dermatology 2009 160 4 835 843
13. Sebastiani M., Manfredi A., Colaci M., Damico R., Malagoli V., Giuggioli D., Ferri C., Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients Arthritis Care and Research 2009 61 5 688 694
14. Hachulla E., Clerson P., Launay D., Lambert M., Morell-Dubois S., Queyrel V., Hatron P.-Y., Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study The Journal of Rheumatology 2007 34 12 2423 2430 (Pubitemid 350230666)
15. Ingraham K., Steen V., Morbidity of digital tip ulceration in scleroderma (abstract) Arthritis and Rheumatism 2006 54 supplement 9 578
16. Steen V., Denton C. P., Pope J. E., Matucci-Cerinic M., Digital ulcers: overt vascular disease in systemic sclerosis Rheumatology 2009 48 19 24
17. Impens A., An exploration and analysis of the current approach to ischemically threatened digit Clinical and Experimental Rheumatology. SP.2.270, 104, 2010
18. Matucci-Cerinic M., Seibold J. R., Digital ulcers and outcomes assessment in scleroderma Rheumatology 2008 47 supplement 5 46 47
19. Thompson A. E., Shea B., Welch V., Fenlon D., Pope J. E., Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis Arthritis and Rheumatism 2001 44 8 1841 1847 (Pubitemid 32758232)
20. Rademaker M., Cooke E. D., Almond N. E., Beacham J. A., Smith R. E., Mant T. G. K., Kirby J. D., Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study British Medical Journal 1989 298 6673 561 564 (Pubitemid 19072096)
21. Fries R., Shariat K., Von Wilmowsky H., Bhm M., Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy Circulation 2005 112 19 2980 2985 (Pubitemid 41612301)
22. Gore J., Silver R., Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis Annals of the Rheumatic Diseases 2005 64 9 1387 (Pubitemid 41206274)
23. Colglazier C. L., Sutej P. G., O'Rourke K. S., Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil Journal of Rheumatology 2005 32 12 2440 2442 (Pubitemid 41780663)
24. Brueckner C., Becker M. O., Kroencke T., Effect of Sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study Annals of the Rheumatic Diseases 2009
25. Shenoy P., Agarwal V., Kumar S., Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double blind randomized cross over trial Arthritis and Rheumatism 2008 58 supplement 9 S402
26. Schiopu E., Hsu V. M., Impens A. J., Rothman J. A., McCloskey D. A., Wilson J. E., Phillips K., Seibold J. R., Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis The Journal of Rheumatology 2009 36 10 2264 2268
27. Biondi M. L., Marasini B., Bassani C., Agostoni A., Increased plasma endothelin levels in patients with Raynaud's phenomenon The New England Journal of Medicine 1991 324 16 1139 1140
28. Yamane K., Miyauchi T., Suzuki N., Yuhara T., Akama T., Suzuki H., Kashiwagi H., Significance of plasma endothelin-1 levels in patients with systemic sclerosis The Journal of Rheumatology 1992 19 10 1566 1571
29. Selenko-Gebauer N., Duschek N., Minimair G., Stingl G., Karlhofer F., Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan Rheumatology 2006 45 supplement 3 45 48
30. Launay D., Diot., Pasquier., Mouthon L., Boullanger N., Fain O., Jego P., Carpentier P., Hatron P.-Y., Hachulla., Bosentan for treatment of active digital ulcers in patients with systemic sclerosis Presse Medicale 2006 35 4 587 592 (Pubitemid 43907154)
31. Garca de la Pea-Lefebvre P., Rodrguez Rubio S., Valero Expsito M., Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients Rheumatology 2008 47 4 464 466
32. Sfikakis P. P., Papamichael C., Stamatelopoulos K. S., Tousoulis D., Fragiadaki K. G., Katsichti P., Stefanadis C., Mavrikakis M., Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis Arthritis and Rheumatism 2007 56 6 1985 1993 (Pubitemid 47110397)
33. Black C., Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis: open lable extension to a double-blind trial Annals of Rheumatic Diseases 2006 65 supplement 2 384
34. Seibold J., Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis Annals of Rheumatic Diseases 2006 65 supplement 2 90
35. Ambach A., Seo W., Bonnekoh B., Gollnick H., Low-dose combination therapy of severe digital ulcers in diffuse progressive systemic sclerosis with the endothelin-1 receptor antagonist bosentan and the phosphodiesterase v inhibitor sildenafil Journal der Deutschen Dermatologischen Gesellschaft 2009 7 10 888 891
36. Gholam P., Sehr T., Enk A., Hartmann M., Successful treatment of systemic-sclerosis-related digital ulcers with a selective endothelin type A receptor antagonist (sitaxentan) Dermatology 2009 219 2 171 173
37. Badesch D. B., Tapson V. F., McGoon M. D., Brundage B. H., Rubin L. J., Wigley F. M., Rich S., Barst R. J., Barrett P. S., Kral K. M., Jbsis M. M., Loyd J. E., Murali S., Frost A., Girgis R., Bourge R. C., Ralph D. D., Elliott C. G., Hill N. S., Langleben D., Schilz R. J., McLaughlin V. V., Robbins I. M., Groves B. M., Shapiro S., Medsger T. A. Jr., Gaine S. P., Horn E., Decker J. C., Knobil K., Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial Annals of Internal Medicine 2000 132 6 425 434 (Pubitemid 30149039)
38. Wigley F. M., Wise R. A., Seibold J. R., McCloskey D. A., Kujala G., Medsger T. A. Jr., Steen V. D., Varga J., Jimenez S., Mayes M., Clements P. J., Weiner S. R., Porter J., Ellman M., Wise C., Kaufman L. D., Williams J., Dole W., Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double- blind study Annals of Internal Medicine 1994 120 3 199 206
39. Wigley F. M., Korn J. H., Csuka M. E., Medsger T. A. Jr., Rothfield N. F., Ellman M., Martin R., Collier D. H., Weinstein A., Furst D. E., Jimenez S. A., Mayes M. D., Merkel P. A., Gruber B., Kaufman L., Varga J., Bell P., Kern J., Marrott P., White B., Simms R. W., Phillips A. C., Seibold J. R., Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study Arthritis and Rheumatism 1998 41 4 670 677 (Pubitemid 28214985)
40. Black C. M., Halkier-Srensen L., Belch J. J. F., Ullman S., Madhok R., Smit A. J., Banga J.-D., Watson H. R., Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study British Journal of Rheumatology 1998 37 9 952 960
41. Vayssairat M., Levesque H., Hachulla E., Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon The Journal of Rheumatology 1996 23 11 1917 1920 (Pubitemid 26376116)
42. Chung L., Fiorentino D., A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Journal of the American Academy of Dermatology 2006 54 5 880 882
43. Schiopu E., Pharmacokinetics of oral treprostinil in patients with systemic sclerosis (SSc) and digital Ulcer disease Arthritis and Rheumatism 2009 60 10 S174
44. Kuwana M., Kaburaki J., Okazaki Y., Yasuoka H., Kawakami Y., Ikeda Y., Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis Arthritis and Rheumatism 2006 54 6 1946 1951 (Pubitemid 43877944)
45. Abou-Raya A., Abou-Raya S., Helmii M., Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers The Journal of Rheumatology 2008 35 9 1801 1808
46. Gliddon A. E., Dor C. J., Black C. M., McHugh N., Moots R., Denton C. P., Herrick A., Barnes T., Camilleri J., Chakravarty K., Emery P., Griffiths B., Hopkinson N. D., Hickling P., Lanyon P., Laversuch C., Lawson T., Mallya R., Nisar M., Rhys-Dillon C., Sheeran T., Maddison P. J., Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril Arthritis and Rheumatism 2007 56 11 3837 3846 (Pubitemid 350100716)
47. Dziadzio M., Denton C. P., Smith R., Howell K., Blann A., Bowers E., Black C. M., Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial Arthritis and Rheumatism 1999 42 12 2646 2655 (Pubitemid 30327186)
48. Sambo P., Amico D., Giacomelli R., Matucci-Cerinic M., Salsano F., Valentini G., Gabrielli A., Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study The Journal of Rheumatology 2001 28 10 2257 2262 (Pubitemid 32947872)
49. Rosato E., Borghese F., Pisarri S., Salsano F., The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients Clinical Rheumatology 2009 28 12 1379 1384
50. Bogoch E. R., Gross D. K., Surgery of the hand in patients with systemic sclerosis: outcomes and considerations The Journal of Rheumatology 2005 32 4 642 648 (Pubitemid 40524695)
51. Ruch D. S., Holden M., Smith B. P., Smith T. L., Koman L. A., Periarterial sympathectomy in scleroderma patients: intermediate-term follow-up The Journal of Hand Surgery 2002 27 2 258 264 (Pubitemid 34241191)
52. Kotsis S. V., Chung K. C., A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia The Journal of Rheumatology 2003 30 8 1788 1792 (Pubitemid 36962456)
53. Hasegawa M., Nagai Y., Tamura A., Ishikawa O., Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis British Journal of Dermatology 2006 155 6 1159 1164 (Pubitemid 44729989)
54. Park J. H., Sung Y.-K., Bae S.-C., Song S.-Y., Seo H. S., Jun J.-B., Ulnar artery vasculopathy in systemic sclerosis Rheumatology International 2009 29 9 1081 1086
55. Taylor M. H., McFadden J. A., Bolster M. B., Silver R. M., Ulnar artery involvement in systemic sclerosis (scleroderma) The Journal of Rheumatology 2002 29 1 102 106 (Pubitemid 34041865)